Viruses like Ebola and Nipah can spark fear, spreading rapidly and causing severe illness. Scientists have long struggled to find a single treatment that works against many viruses, as each one seems so different. But a new study offers hope by targeting a common weak spot: the sugar molecules, or glycans, that many viruses rely on to infect us.
Sugars: The Key to Stopping Viruses
Most dangerous viruses, like the one causing Ebola, are wrapped in a protective envelope studded with proteins coated in glycans. These sugars help the virus sneak into our cells, fuse with them, and hide from our immune system. By focusing on these glycans, which are similar across many viruses, researchers believe they can develop a treatment that works against a wide range of threats.
In a study published in Science Advances on August 27, 2025, researchers tested 57 synthetic molecules called carbohydrate receptors (SCRs). These molecules are designed to stick to the sugars on viruses, blocking their ability to infect cells. Four of these—SCR005, SCR007, SCR064, and SCR065—stood out, cutting infection by more than half in lab tests against viruses like SARS-CoV-2, Ebola, and Nipah. They even showed promise against rotavirus, a virus without an envelope, suggesting these molecules could work against an even broader range of diseases.
Protection That Works in Animals
The researchers didn’t stop at lab tests. They took two of the best molecules, SCR005 and SCR007, and tested them in mice infected with a deadly version of SARS-CoV-2, similar to severe human cases. A single dose, given through the nose, made a big difference. Mice treated with SCR007 had a 90% survival rate after two weeks, with barely any weight loss, compared to untreated mice or those given a less effective molecule, which lost significant weight and died within nine days. SCR005 also helped, with 30% of mice surviving.
The treated mice had far less virus in their lungs and brains, and their inflammation levels—key drivers of severe disease—dropped dramatically. Importantly, the treatment was safe, with no major side effects even at high doses. This suggests these molecules could be used to prevent or treat infections, potentially protecting us from unknown future viruses, often called “Disease X.”
How It Works and What’s Next
The study revealed that SCR007 stops viruses early, preventing them from attaching to our cells. For some viruses, like Nipah, it also blocks the fusion process, where the virus merges with our cells to release its genetic material. The molecules target specific sugar structures on the virus, which are less likely to change than other parts, making it harder for viruses to develop resistance.
This breakthrough could simplify how we fight viral outbreaks. Instead of developing a new drug for every virus, targeting their shared sugar coating could offer a universal solution. The researchers are now planning human trials and tests against new virus variants. If successful, this approach could not only tackle enveloped viruses like COVID-19 but also other types, opening the door to a new era of antiviral treatments.
Leave a Reply